Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
FierceBiotech5d
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
FiercePharma6d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Lilly Profit View ‘Enough to Pacify Investors’ After Sales Miss
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
Eli Lilly reports mixed earnings, increases 2025 guidance
Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...
ABC News6d
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...